Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease
Sônia A. L. Corrêa, Katherine L. Eales
Journal of Signal Transduction (2012) Vol. 2012, pp. 1-12
Open Access | Times Cited: 233

Showing 1-25 of 233 citing articles:

Involvement of p38 MAPK in Synaptic Function and Dysfunction
Chiara Falcicchia, Francesca Tozzi, Ottavio Arancio, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5624-5624
Open Access | Times Cited: 145
The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer’s Disease
Zhenzhen Liu, Tao Li, Ping Li, et al.
Oxidative Medicine and Cellular Longevity (2015) Vol. 2015, pp. 1-12
Open Access | Times Cited: 174
p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease.
Saurabh Kumar Jha, Niraj Kumar Jha, Rohan Kar, et al.
PubMed (2015) Vol. 4, Iss. 2, pp. 67-86
Closed Access | Times Cited: 135
Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer’s disease
Sima Kianpour Rad, Aditya Arya, Hamed Karimian, et al.
Drug Design Development and Therapy (2018) Vol. Volume 12, pp. 3999-4021
Open Access | Times Cited: 122
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Nicole Maphis, Shanya Jiang, Guixiang Xu, et al.
Alzheimer s Research & Therapy (2016) Vol. 8, Iss. 1
Open Access | Times Cited: 118
Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia Through Nrf2-Dependent Mechanisms
Uchechukwu P. Okorji, Ravikanth Velagapudi, Abdelmeneim El‐Bakoush, et al.
Molecular Neurobiology (2015) Vol. 53, Iss. 9, pp. 6426-6443
Closed Access | Times Cited: 104
Dysregulation of autophagy and stress granule-related proteins in stress-driven Tau pathology
Joana Silva, Sara Rodrigues, Belém Sampaio‐Marques, et al.
Cell Death and Differentiation (2018) Vol. 26, Iss. 8, pp. 1411-1427
Open Access | Times Cited: 97
Analysis of induced pluripotent stem cells carrying 22q11.2 deletion
Manabu Toyoshima, Wado Akamatsu, Yohei Okada, et al.
Translational Psychiatry (2016) Vol. 6, Iss. 11, pp. e934-e934
Open Access | Times Cited: 94
Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer’s and Vascular Dementia Drugs
Solomon Habtemariam
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 458-458
Open Access | Times Cited: 89
Map kinase signaling as therapeutic target for neurodegeneration
Touqeer Ahmed, Abida Zulfiqar, Sandro Argüelles, et al.
Pharmacological Research (2020) Vol. 160, pp. 105090-105090
Closed Access | Times Cited: 78
Hyperbaric Oxygen Treatment—From Mechanisms to Cognitive Improvement
Irit Gottfried, Nofar Schottlender, Uri Ashery
Biomolecules (2021) Vol. 11, Iss. 10, pp. 1520-1520
Open Access | Times Cited: 75
Therapeutic Potential of Vital Transcription Factors in Alzheimer’s and Parkinson’s Disease With Particular Emphasis on Transcription Factor EB Mediated Autophagy
Sachchida Nand, Neeraj Tiwari, Payal Singh, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 73
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Niels D. Prins, John Harrison, Hui‐May Chu, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 63
GSK-3β: An exuberating neuroinflammatory mediator in Parkinson's disease
Sabiya Samim Khan, Sushmita Janrao, Saurabh Srivastava, et al.
Biochemical Pharmacology (2023) Vol. 210, pp. 115496-115496
Open Access | Times Cited: 40
Limonene, a Monoterpene, Mitigates Rotenone-Induced Dopaminergic Neurodegeneration by Modulating Neuroinflammation, Hippo Signaling and Apoptosis in Rats
Lujain Bader Eddin, Sheikh Azimullah, Niraj Kumar Jha, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5222-5222
Open Access | Times Cited: 22
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy
Mari Aikio, Hana M. Odeh, Heike J. Wobst, et al.
Cell Reports (2025) Vol. 44, Iss. 1, pp. 115205-115205
Open Access | Times Cited: 1
Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse Models
Saktimayee M. Roy, Valerie Grum‐Tokars, James P. Schavocky, et al.
ACS Chemical Neuroscience (2015) Vol. 6, Iss. 4, pp. 666-680
Open Access | Times Cited: 85
Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds
Hongjia Zhang, Lan Bai, Jun He, et al.
European Journal of Medicinal Chemistry (2017) Vol. 141, pp. 257-272
Closed Access | Times Cited: 81
Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats
John Alam
Journal of Alzheimer s Disease (2015) Vol. 48, Iss. 1, pp. 219-227
Open Access | Times Cited: 74
Hippocampal metabotropic glutamate receptor long‐term depression in health and disease: focus on mitogen‐activated protein kinase pathways
Thomas M. Sanderson, Ellen L. Hogg, Graham L. Collingridge, et al.
Journal of Neurochemistry (2016) Vol. 139, Iss. S2, pp. 200-214
Open Access | Times Cited: 63
The Nuclear Translocation of Mitogen-Activated Protein Kinases: Molecular Mechanisms and Use as Novel Therapeutic Target
Karen Flores, Suresh Singh Yadav, Arieh A. Katz, et al.
Neuroendocrinology (2018) Vol. 108, Iss. 2, pp. 121-131
Closed Access | Times Cited: 63
Prions activate a p38 MAPK synaptotoxic signaling pathway
Fang Cheng, Bei Wu, Nhat T. T. Le, et al.
PLoS Pathogens (2018) Vol. 14, Iss. 9, pp. e1007283-e1007283
Open Access | Times Cited: 60
Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effects
Riham M. Mansour, Maha A.E. Ahmed, Ayman E. El-Sahar, et al.
Toxicology and Applied Pharmacology (2018) Vol. 358, pp. 76-85
Closed Access | Times Cited: 59
Atypical p38 Signaling, Activation, and Implications for Disease
Jeremy C. Burton, William Antoniades, Jennifer Okáľová, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4183-4183
Open Access | Times Cited: 55
When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer’s and Huntington’s Disease
Santosh R. D’Mello
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5911-5911
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top